Recent histone deacetylase inhibitors in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer metastasis significantly increases mortality, with traditional chemotherapy often exhibiting limited efficacy and severe side effects.
• Histone deacetylase (HDAC) enzymes are crucial for chromatin structure and gene regulation, playing a key role in cancer progression and metastasis.
• HDAC inhibitors (HDACi) offer a therapeutic strategy by modulating gene expression, inducing cell-cycle arrest, and promoting apoptosis in cancer cells.

Purpose of the Study:

• To review the current landscape of HDAC inhibitors in cancer therapeutics.
• To highlight recent clinical trials and patents (2019 onwards) related to HDACi.
• To provide an overview of HDACi classes, mechanisms of action, and efficacy in various cancers.

Main Methods:

• Literature review focusing on HDAC inhibitors in cancer therapy.
• Analysis of preclinical and clinical efficacy data.
• Examination of recent patents and clinical trial data from 2019 to present.

Main Results:

• Several HDACi drugs (e.g., vorinostat, tucidinostat) are approved and show efficacy in various cancers like cervical cancer, lymphoma, and breast cancer.
• Subtype-selective HDACi, such as tucidinostat, target specific HDAC classes (1, 2, 3, 10) with promising results.
• Recent data from 2019 onward indicates ongoing research and development in HDACi for cancer treatment.

Conclusions:

• HDAC inhibitors represent a significant advancement in cancer therapy, offering improved efficacy and targeted mechanisms.
• The continued investigation of HDACi through clinical trials and patent filings underscores their potential as next-generation chemotherapy agents.
• HDACi demonstrate broad applicability across multiple cancer types, highlighting their therapeutic versatility.